{
  "image_filename": "table_p6_det_5_006.png",
  "image_path": "Grohskopf_et_al.__2023_/extracted/figures/table_p6_det_5_006.png",
  "image_type": "Table",
  "page_number": 6,
  "block_id": "det_5_006",
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "supports_claim": false,
  "explanation": "A table listing influenza vaccine types (egg-based IIV4s, cell culture-based IIV4, recombinant RIV4, live-attenuated LAIV4) alongside their contraindications and precautions. The table only provides safety information (contraindications and precautions) for different vaccine platforms and contains no data on immune response breadth, cross-protection, or mismatch season efficacy, so it does not support the claim.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "A table listing influenza vaccine types (egg-based IIV4s, cell culture-based IIV4, recombinant RIV4, live-attenuated LAIV4) alongside their contraindications and precautions.",
    "evidence_found": null,
    "reasoning": "The table only provides safety information (contraindications and precautions) for different vaccine platforms and contains no data on immune response breadth, cross-protection, or mismatch season efficacy, so it does not support the claim.",
    "confidence_notes": null
  }
}